| SAN DIEGO, Feb. 1, 2012 /PRNewswire/ -- Aethlon Medical, Inc . (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the administration of Hemopurifier® therapy during the first three days of standard of care peginterferon+ribavirin (PR) drug therapy has demonstrated both immediate and rapid virologic responses in genotype-1 infected HCV patients. An immediate virolog...continued AEMD trials leprosy awards |
Wednesday, February 1, 2012
Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier( Treatment Protocol
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment